On the 14th, Roche Korea announced that its anti-PD-L1 immuno-oncology drug Tecentriq (atezolizumab) was approved as adjuvant therapy following resection in patients with early-stage non-small-cell-lung cancer, and became the first immunotherapy to receive approval for the indication.

Tecentriq may now be used as an adjuvant treatment following complete resection and platinum-based chemotherapy in adult patients with stage II to IIIA NSCLC with PD-L1 expression of 50% or higher on tumor cells (TC).

With this approval, Tecentriq became the first cancer immunotherapy to be approved as adjuvant therapy in early-stage NSCLC in Korea.

The indication extension was approved bas